Back
Septerna's Oral Drug SEP-631 Shows Full Efficacy in Phase 1 Trial
Back
Stock News
Themes
Septerna's Oral Drug SEP-631 Shows Full Efficacy in Phase 1 Trial
Septerna's Oral Drug SEP-631 Shows Full Efficacy in Phase 1 Trial
Edgen Stock
·
Mar 01 2026, 15:05
Share to
Share to
Copy link
source:
[1] Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Recommend
Wendy's Stock Hits 52-Week Low Despite Earnings Beat
Mar 01 2026, 15:36
Nokia and Ericsson Partner to Accelerate Open 5G Networks
Mar 01 2026, 15:35
US Military Denies Iranian Missile Attack on Carrier
Mar 01 2026, 15:20
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Mar 01 2026, 15:05Edgen Stock·Mar 01 2026, 15:05
Edgen Stock·Mar 01 2026, 15:05